KZR Stock Summary and Trading Ideas (Kezar Life Sciences | NASDAQ:KZR)

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences trades on the NASDAQ stock market under the symbol KZR.

As of April 24, 2024, KZR stock price declined to $0.80 with 413,761 million shares trading.

KZR has a beta of 2.90, meaning it tends to be more sensitive to market movements. KZR has a correlation of 0.18 to the broad based SPY ETF.

KZR has a market cap of $58.34 million. This is considered a Micro Cap stock.

In the last 3 years, KZR stock traded as high as $18.55 and as low as $.67.

The top ETF exchange traded funds that KZR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

KZR has underperformed the market in the last year with a price return of -67.8% while the SPY ETF gained +24.2%. KZR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.3% and -3.3%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

KZR support price is $.79 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KZR stock will trade within this expected range on the day.